This meta-study was published in the journal Frontiers In Pharmacology in November 2021. It examined the phenomenon known as chemotherapy-induced cognitive impairment (CICI), commonly known as chemofog or chemobrain. It is a common side-effect of standard cancer treatments, and has been shown to last well beyond the end of treatment.
The review focused on the two main processes associated with the development of CICI: neuroinflammation and oxidative stress, and there is evidence that the endogenous cannabinoid system (ECS) as a new therapeutic target against CICI.
"The data collected elucidate the positive outcomes of cannabinoid-based drugs in the relief of [Parkinson’s disease (PD), Alzheimer’s disease (AD)] PD- and AD-side effects in human patients. These results highlight the possible therapeutic potential of cannabinoid drugs in the treatment of CICI. The lack of clinical evidence supporting the anti-cancer role described of the ECS in animal and in vitro models, emphasizes the importance of translating the preclinical findings into humans."
The link to the paper with LOTS of good references is at the Frontiers In Pharmacology website here.